Nuvectis Pharma (NVCT)
NASDAQ:NVCT
US Market
Holding NVCT?
Track your performance easily

Nuvectis Pharma (NVCT) Income Statement

75 Followers

Nuvectis Pharma Income Statement

Last quarter (Q3 2024), Nuvectis Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Nuvectis Pharma's net income was $-4.15M. See Nuvectis Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
---$ 0.00$ 0.00
Cost of Revenue
$ 3.50M$ 3.50M$ -2.17M--
Gross Profit
$ -3.50M$ -3.50M$ 2.17M--
Operating Expense
$ 20.26M$ 22.90M$ 19.23M$ 12.89M$ 10.00K
Operating Income
$ -20.26M$ -22.90M$ -19.23M$ -12.89M$ -10.00K
Net Non Operating Interest Income Expense
-$ -637.00K-$ 4.00K$ 0.00
Other Income Expense
-----
Pretax Income
$ -20.26M$ -22.26M$ -19.23M$ -12.89M$ -10.00K
Tax Provision
--$ 0.00--
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -19.37M$ -22.26M$ -19.09M$ -12.89M$ -10.00K
Basic EPS
$ -1.16$ -1.43$ -1.51$ -1.09$ >-0.01
Diluted EPS
$ -1.16$ -1.43$ -1.51$ -1.09$ >-0.01
Basic Average Shares
$ 66.91M$ 15.56M$ 12.66M$ 12.72M$ 12.72M
Diluted Average Shares
$ 66.91M$ 15.56M$ 12.66M$ 12.72M$ 12.72M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 23.76M$ 22.90M$ 17.06M$ 12.89M$ 10.00K
Net Income From Continuing And Discontinued Operation
$ -19.37M$ -22.26M$ -19.09M$ -12.89M$ -10.00K
Normalized Income
$ -18.69M--$ -12.89M$ -10.00K
Interest Expense
-----
EBIT
$ -19.84M$ -22.90M$ -19.23M$ -12.89M$ -10.00K
EBITDA
$ -19.84M$ -22.90M$ -19.23M$ -12.89M$ -10.00K
Currency in USD

Nuvectis Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis